1.
Turning the tide on
cancer drug costs
The increase in the median monthly cost
of cancer drugs in the US since 19902
©2015EYGMLimited.AllRightsReserved.EYGno.FN0236.EDNone
1 A rising tide of new cancer
drugs helps patients.
These contracts are complex to
build, but can provide a strong
foundation for patient access.
To hold back the tide of oncology drug costs, payers …3
... experiment with new models
US payers test indication-specific
pricing, taking advantage of
four new drug value tools.
Since 2006, NICE has issued negative
recommendations for
of the cancer
drugs reviewed.3
... limit patient access
Innovative risk-sharing agreements
are another way to turn the tide.4
of the contracts
are for cancer
drugs.4
65%The number of
risk-sharing contracts
created in the
UK and Italy since 2006
90
Sources: 1
U.S. Food & Drug Administration, Memorial Sloan Kettering Cancer Center, Decision Resources. 2
Peter Bach, Memorial Sloan Kettering Cancer Center,
Center for Health Policy and Outcomes, "Price and Value of Cancer Drug," 2015. 3
EY, National Institute for Health and Care Excellence (NICE).
4
Van de Vooren, et al., “Market-access agreements for anti-cancer drugs,” J R Soc Med (108): 166–170, 2015.
Since 1990,
new cancer drugs have
been approved in the US.
117
50Another
could reach the market by 2020.1
$41%
>700%
2 This wave of innovation
could drown payers.